{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T05:41:31Z","timestamp":1769233291808,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.bioorg.2021.105483","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T03:06:22Z","timestamp":1637118382000},"page":"105483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Discovery of N-(2-benzyl-4-oxochroman-7-yl)-2-(5-(ethylsulfonyl) pyridin-2-yl) acetamide (b12) as a potent, selective, and orally available novel retinoic acid receptor-related orphan receptor \u03b3t inverse agonist"],"prefix":"10.1016","volume":"119","author":[{"given":"Lei","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Gu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Israa","family":"Assani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mu-Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Feng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shen-Min","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Xin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2021.105483_b0005","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/ni.3742","article-title":"Interleukin 17 is a chief orchestrator of immunity","volume":"18","author":"Veldhoen","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bioorg.2021.105483_b0010","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrrheum.2015.53","article-title":"The IL-23\u2212IL-17 axis in inflammatory arthritis","volume":"11","author":"Lubberts","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bioorg.2021.105483_b0015","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ni1261","article-title":"A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17","volume":"6","author":"Park","year":"2005","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.bioorg.2021.105483_b0020","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","article-title":"The orphan nuclear receptor ROR\u03b3t directs the differentiation program of proinflammatory IL-17+ T helper cells","volume":"126","author":"Ivanov","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2021.105483_b0025","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2021.105483_b0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s13555-016-0102-0","article-title":"Ixekizumab for the treatment of psoriasis: a review of phase III traials","volume":"6","author":"Farahnik","year":"2016","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.bioorg.2021.105483_b0035","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1021\/jm401901d","article-title":"Modulators of the nuclear receptor retinoic acid receptor-related orphan receptor-\u03b3 (ROR\u03b3 or RORc)","volume":"57","author":"Fauber","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105483_b0040","doi-asserted-by":"crossref","first-page":"10976","DOI":"10.1021\/acs.jmedchem.8b00588","article-title":"Combating autoimmune diseases with retinoic acid receptor related orphan receptor-\u03b3 (ROR\u03b3 or RORc) inhibitors: hits and misses","volume":"61","author":"Pandya","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105483_b0045","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu. Rev. Immunol."},{"issue":"6248","key":"10.1016\/j.bioorg.2021.105483_b0050","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1126\/science.aaa4282","article-title":"Impairment of immunity to candida and mycobacterium in humans with bi-allelic RORC mutations","volume":"349","author":"Okada","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2021.105483_b0055","doi-asserted-by":"crossref","unstructured":"Richard G. Langley, Boni E. Elewski, Mark Lebwohl, Kristian Reich, Christopher E.M. Griffiths, Kim Papp, Llu\u00eds Puig, et al., Secukinumab in Plaque Psoriasis \u2014 Results of Two Phase 3 Trials, New Engl. J. Med. 371 (2014) 326\u2013338.","DOI":"10.1056\/NEJMoa1314258"},{"key":"10.1016\/j.bioorg.2021.105483_b0060","doi-asserted-by":"crossref","unstructured":"Christopher E.M. Griffiths, Kristian Reich, Mark Lebwohl, Peter van de Kerkhof, Carle Paul, Alan Menter, Gregory S. Cameron, Janelle Erickson, Lu Zhang, Roberta J. Secrest, Susan Ball, Daniel K. Braun, Olawale O. Osuntokun, Michael P. Heffernan, Brian J. Nickoloff, Kim Papp, Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials, The Lancet 386 (2015) 541\u2013551.","DOI":"10.1016\/S0140-6736(15)60125-8"},{"key":"10.1016\/j.bioorg.2021.105483_b0065","doi-asserted-by":"crossref","unstructured":"Kim A. Papp, Craig Leonardi, Alan Menter, Jean-Paul Ortonne, James G. Krueger, Gregory Kricorian, Girish Aras, Juan Li, Chris B. Russell, H.Z. Elizabeth, Thompson, Scott Baumgartner, Brodalumab, an anti\u2013interleukin-17\u2013receptor antibody for psoriasis, New Engl. J. Med. 366 (2012) 1181\u20131189.","DOI":"10.1056\/NEJMoa1109017"},{"key":"10.1016\/j.bioorg.2021.105483_b0070","doi-asserted-by":"crossref","first-page":"7796","DOI":"10.1021\/acs.jmedchem.8b00783","article-title":"Potent and orally bioavailable inverse agonists of ROR\u03b3t resulting from structure-based design","volume":"61","author":"Narjes","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105483_b0075","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1021\/acs.jmedchem.8b00061","volume":"61","author":"Kono","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105483_b0080","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1021\/acsmedchemlett.5b00253","article-title":"SAR exploration guided by LE and Fsp3: discovery of a selective and orally efficacious ROR\u03b3 inhibitor","volume":"7","author":"Hirata","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2021.105483_b0085","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejmech.2019.01.082","article-title":"Discovery of N-indanyl benzamides as potent RORgt inverse agonists","volume":"167","author":"Tian","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105483_b0090","doi-asserted-by":"crossref","first-page":"6724","DOI":"10.1021\/acs.jmedchem.8b00529","article-title":"Optimizing a weakly binding fragment into a potent ROR\u03b3t inverse agonist with efficacy in an in vivo inflammation model","volume":"61","author":"Carcache","year":"2018","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.bioorg.2021.105483_b0095","doi-asserted-by":"crossref","first-page":"10519","DOI":"10.1021\/acs.jmedchem.0c02178","article-title":"Agonist lock touched and untouched retinoic acid receptor-related orphan receptor-\u03b3t (ROR\u03b3t) inverse agonists: classification based on the molecular mechanisms of action","volume":"64","author":"Sun","year":"2021","journal-title":"J. Med. Chem.."},{"issue":"7344","key":"10.1016\/j.bioorg.2021.105483_b0100","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nature10075","article-title":"Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand","volume":"472","author":"Solt","year":"2011","journal-title":"Nature"},{"issue":"26","key":"10.1016\/j.bioorg.2021.105483_b0105","doi-asserted-by":"crossref","first-page":"22707","DOI":"10.1074\/jbc.C111.250407","article-title":"Ursolic acid suppresses interleukin-17 (IL-17) production by selectively antagonizing the function of RORgamma t protein","volume":"286","author":"Xu","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2021.105483_b0110","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1021\/acs.jmedchem.5b00597","volume":"58","author":"Fauber","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105483_b0115","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1517\/13543776.2016.1153066","article-title":"Retinoid-related orphan receptor gamma t (ROR\u03b3t) inhibitors from Vitae Pharmaceuticals (WO2015116904) and structure proposal for their Phase I candidate VTP-43742","volume":"26","author":"Gege","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2021.105483_b0120","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1021\/acsmedchemlett.5b00122","article-title":"Discovery of biaryl amides as potent, orally bioavailable, and CNS penetrant ROR\u03b3t inhibitors","volume":"6","author":"Wang","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2021.105483_b0125","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/mol.109.060905","article-title":"The benzenesulfonamide T0901317 [N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-(trifluoromethyl)ethyl]phenyl] benzenesulfonamide] is a novel retinoic acid receptor-related orphan receptor-\u03b1\/\u03b3 inverse agonist","volume":"77","author":"Kumar","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bioorg.2021.105483_b0130","unstructured":"F. Narjes, The discovery of AZD0284, an inverse agonist of the nuclear receptor ROR\u03b3, Drug Design and Delivery Symposium, October 26, 2017; American Chemical Society: Washington DC, 2017. https:\/\/www.acs.org\/content\/acs\/en\/acs-webinars\/drug-discovery\/psoriasis.html."},{"key":"10.1016\/j.bioorg.2021.105483_b0135","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1146\/annurev-pharmtox-010919-023711","article-title":"(Inverse) Agonists of Retinoic Acid-Related Orphan Receptor \u03b3: Regulation of immune responses, inflammation, and autoimmune disease","volume":"60","author":"Jetten","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105483_b0140","doi-asserted-by":"crossref","first-page":"11066","DOI":"10.1038\/s41598-021-90497-9","article-title":"Preclinical and clinical characterization of the ROR\u03b3t inhibitor JNJ-61803534","volume":"11","author":"Xue","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2021.105483_b0145","doi-asserted-by":"crossref","first-page":"9132","DOI":"10.1038\/s41598-021-88492-1","article-title":"Discovery of a novel ROR\u03b3 antagonist with skin-restricted exposure for topical treatment of mild to moderate psoriasis","volume":"11","author":"Liu","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2021.105483_b0150","unstructured":"An ascending multiple dose study withVTP-43742in healthy volunteers. ClinicalTrials.Gov; U.S. National Insitutes of Health: Bethesda, MD, 2018; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03724292?term=vtp+43742&draw=2&rank=1."},{"key":"10.1016\/j.bioorg.2021.105483_b0155","unstructured":"An ascending multiple dose study withVTP-43742in healthy volunteers and psoriatic patients. ClinicalTrials.Gov; U.S. National Insitutes of Health: Bethesda, MD, 2018; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02555709?term=vtp+43742&draw=2&rank=2."},{"key":"10.1016\/j.bioorg.2021.105483_b0160","unstructured":"L. Zhuang, Discovery of VTP-43742, a ROR\u03b3t inverse agonist for the treatment of psoriasis, in: 13th Winter Conference on Medicinal and Bioorganic Chemistry, Steamboat Springs, CO. January, 2017, pp. 22\u201326."},{"issue":"13","key":"10.1016\/j.bioorg.2021.105483_b0165","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/cmdc.201700278","article-title":"Structural states of ROR\u03b3t: X-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds","volume":"12","author":"Kallen","year":"2017","journal-title":"ChemMedChem."},{"key":"10.1016\/j.bioorg.2021.105483_b0170","doi-asserted-by":"crossref","first-page":"8833","DOI":"10.1038\/ncomms9833","article-title":"Identification of an allosteric binding site for ROR\u03b3t inhibition","volume":"6","author":"Scheepstra","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2021.105483_b0175","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/cmdc.201700278","article-title":"Structural states of ROR\u03b3t: X-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds","volume":"12","author":"Kallen","year":"2017","journal-title":"ChemMedChem."},{"issue":"24","key":"10.1016\/j.bioorg.2021.105483_b0180","doi-asserted-by":"crossref","first-page":"10976","DOI":"10.1021\/acs.jmedchem.8b00588","article-title":"Combating autoimmune diseases with retinoic acid receptor-related orphan receptor-\u03b3 (ROR\u03b3 or RORc) inhibitors: hits and misses","volume":"61","author":"Pandya","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105483_b0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13543776.2017.1262350","article-title":"ROR\u03b3t inhibitors as potential back-ups for the phase II candidate VTP-43742 from Vitae Pharmaceuticals: patent evaluation of WO2016061160 and US20160122345","volume":"27","author":"Gege","year":"2017","journal-title":"Expert Opin. Ter. Pat."},{"issue":"11","key":"10.1016\/j.bioorg.2021.105483_b0190","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nrd2445","article-title":"The influence of drug-like concepts on decision-making in medicinal chemistry","volume":"6","author":"Leeson","year":"2007","journal-title":"Nature Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2021.105483_b0195","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1021\/jm000942e","article-title":"Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties","volume":"43","author":"Ertl","year":"2000","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2021.105483_b0200","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105483_b0205","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"Van der Fits","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.bioorg.2021.105483_b0210","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/jid.2012.318","article-title":"An alternative pathway of imiquimod-Induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor a signaling","volume":"133","author":"Malki","year":"2013","journal-title":"J. Invest. Dermatol."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821008610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821008610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:24:10Z","timestamp":1758615850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206821008610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":42,"alternative-id":["S0045206821008610"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.105483","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of N-(2-benzyl-4-oxochroman-7-yl)-2-(5-(ethylsulfonyl) pyridin-2-yl) acetamide (b12) as a potent, selective, and orally available novel retinoic acid receptor-related orphan receptor \u03b3t inverse agonist","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.105483","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105483"}}